What is Inhibrx Biosciences, Inc.'s financing cash flow?

Inhibrx Biosciences, Inc. (INBX) reported financing cash flow of $75.46M in Q1 2026.

How has Inhibrx Biosciences, Inc.'s financing cash flow changed year-over-year?

Inhibrx Biosciences, Inc.'s financing cash flow decreased by 24.4% year-over-year, from $99.84M to $75.46M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Inhibrx Biosciences, Inc. INBX Financing Cash Flow

Financing Cash Flow at other companies

PfizerPFE

-$2.86B+45.4%

Rogers CorporationROG

-$1.6M0.0%

Merck & Co.MRK

-$2.98B+48.2%

Gilead SciencesGILD

-$4.24B-23.7%

Nuvation BioNUVB

$44K-92.0%

ArriVent BioPharma, Inc.AVBP

$54.87M+712%

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s financing cash flow?: Inhibrx Biosciences, Inc. (INBX) reported financing cash flow of $75.46M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s financing cash flow changed year-over-year?: Inhibrx Biosciences, Inc.'s financing cash flow decreased by 24.4% year-over-year, from $99.84M to $75.46M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.